Effectiveness of bupropion sustained release for smoking cessation in a health care setting - A randomized trial

被引:115
作者
Swan, GE
McAfee, T
Curry, SJ
Jack, LM
Javitz, H
Dacey, S
Bergman, K
机构
[1] SRI Int, Ctr Hlth Sci, Menlo Pk, CA 94025 USA
[2] Grp Hlth Cooperat Puget Sound, Ctr Hlth Promot, Seattle, WA 98121 USA
[3] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA
[4] Grp Hlth Cooperat Puget Sound, Ctr Pharm Adm, Seattle, WA 98101 USA
关键词
D O I
10.1001/archinte.163.19.2337
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The efficacy of bupropion hydrochloride sustained release (SR) (Zyban) for smoking cessation has been evaluated in clinical trials that included frequent in-person behavioral counseling, but not in actual practice settings. Objective: To determine the differential effectiveness of 2 doses of bupropion SR in combination with behavioral interventions of minimal to moderate intensity in an actual practice setting. Design: Open-label randomized trial, with 1 year of follow-up. Setting: A large health system (Group Health Cooperative) based in Seattle. Participants: Adult smokers (N=1524) interested in quitting smoking. Interventions: Participants were randomly assigned to receive 1 of 4 combinations of bupropion SR (150 or 300 mg) and behavioral counseling (minimal or moderate intensity). Main Outcome Measures: The primary outcome measure was self-reported point-prevalence 7-day nonsmoking status at 3 and 12 months following the target quit date. Secondary outcomes included adverse and abstinence effects reported since beginning treatment with bupropion SR. Results: At 3 months, a significantly higher rate of nonsmoking was observed among those receiving the larger bupropion SR dose (P=.005). At 12 months, moderate intensity counseling was associated significantly with a higher rate of nonsmoking (P=.001). At 3 months, the higher dose was associated with a significantly increased frequency of self-reported symptoms such as difficulty sleeping (P=.02), difficulty concentrating (P=.02), shakiness/tremor (P=.002), and gastrointestinal problems (P=.005)and a decreased frequency of reported desire to smoke (P=.001). Conclusions: In this actual practice setting, the combination of bupropion SR and minimal or moderate counseling was associated with 1-year quit rates of 23.6% to 33.2%. This suggests that existing health care systems can substantially decrease tobacco use rates among their enrollees if they provide these modest interventions.
引用
收藏
页码:2337 / 2344
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 1989, SAS STAT US GUID VER
[2]  
[Anonymous], 2001, The California tobacco control program: A decade of progress, results from the California tobacco surveys, 1990-1999
[3]   HOPKINS SYMPTOM CHECKLIST (HSCL) - SELF-REPORT SYMPTOM INVENTORY [J].
DEROGATIS, LR ;
LIPMAN, RS ;
RICKELS, K ;
UHLENHUTH, EH ;
COVI, L .
BEHAVIORAL SCIENCE, 1974, 19 (01) :1-15
[4]   Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice [J].
Farmer, KC .
CLINICAL THERAPEUTICS, 1999, 21 (06) :1074-1090
[5]  
Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244
[6]  
Fiore MC., 2000, TREATING TOBACCO USE
[7]   BIOCHEMICAL VALIDATION OF SMOKING STATUS - PROS, CONS, AND DATA FROM 4 LOW-INTENSITY INTERVENTION TRIALS [J].
GLASGOW, RE ;
MULLOOLY, JP ;
VOGT, TM ;
STEVENS, VJ ;
LICHTENSTEIN, E ;
HOLLIS, JF ;
LANDO, HA ;
SEVERSON, HH ;
PEARSON, KA ;
VOGT, MR .
ADDICTIVE BEHAVIORS, 1993, 18 (05) :511-527
[8]  
Goldstein MG, 1998, J CLIN PSYCHIAT, V59, P66
[9]   Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo-controlled study [J].
Gonzales, DH ;
Nides, MA ;
Ferry, LH ;
Kustra, RP ;
Jamerson, BD ;
Segall, N ;
Herrero, LA ;
Krishen, A ;
Sweeney, A ;
Buaron, K ;
Metz, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (06) :438-444
[10]  
HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119